Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
Addressing OUD Treatment Gaps & Improving Patient Outcomes
July 23rd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
Braeburn on BRIXADI® Research and Addressing Fentanyl's Impact on OUD
July 22nd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Pharmacy Closure Contributors & Long-Term Consequences
June 27th 2024In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, identifies the main factors contributing to closures of pharmacies big and small and some potential long-term consequences for public health if they continue.
